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Abstract
Background: Glucocorticoid resistance is a rare, sporadic or familial condition caused by mutation of the gene
encoding the glucocorticoid receptor (GR). Clinically it is characterized by symptoms developed due to local,
tissue-specific, or generalized partial insensitivity to glucocorticoids.
Case presentation: A 31-year-old woman was evaluated because of infertility at the Endocrine Unit of the 2nd
Department of Medicine, Semmelweis University. During her laboratory investigations, elevated serum and salivary
cortisol were observed which failed to be suppressed after administration of 1 mg dexamethasone. 24 h urinary
cortisol was increased, but a normal midnight serum cortisol was detected suggesting a maintained circadian
rhythm. Plasma dehydroepiandrosterone-sulfate and androstendione levels were also elevated. Repeated plasma
ACTH measurements indicated slightly elevated or normal values. Bone mineral density was normal. All laboratory
results confirmed the diagnosis of glucocorticoid resistance. Genetic counseling followed by Sanger sequencing of
the coding region of the gene encoding human glucocorticoid receptor was performed and a missense mutation
(Arg714Gln, R714Q) in a heterozygous form was detected. Following family screening, the same mutation was
found in her clinically-healthy 35-year-old sister who had no fertility problems.This variant was not detected in more
than 60 patients and controls tested either for glucocorticoid resistance or Cushing’s syndrome in our Laboratory
and it was absent in Exome Variant Server, HumanGene Mutation Database and ExAC databases.
Conclusions: Our case fulfils the diagnostic criteria of glucocorticoid resistance, also named Chrousos syndrome.
The glucocorticoid receptor gene mutation detected in our patient has been already reported in a 2-year-old child
with hypoglycaemia, hypokalaemia, hypertension and premature puberty. These distinct phenotypes may suggest
that other factors may modify the functional consequences of the R714Q variant of GR.
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Background
Glucocorticoids are essential steroid hormones involved
in the regulation of adaptation to stress, carbohydrate-,
protein-, fat-, calcium- and bone-metabolism, immune
function, growth and behavioural regulation. They exert
their actions through the glucocorticoid receptor (GR).
The glucocorticoid receptor gene (GR, NR3C1) is
located on chromosome 5q31 and contains 9 exons. The
protein coding part starts from the second exon. The
receptor consists of distinct domains including the N-
terminal domain (NTD), the central DNA binding
domain and the C-terminal ligand binding domain
(LBD) [1, 2]. In the absent of ligand, GR is located in
the cytoplasm in a multi-protein complex containing
heat shock proteins and other chaperons [3]. Upon
ligand binding, GR is released from this complex and
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translocates into the nucleus. In the nucleus it binds
to the DNA through specific DNA sequences (GRE -
glucocorticoid response element) and regulates the
transcription of target genes [2, 4, 5]. The LBD
domain contains a ligand-dependent activation func-
tion (AF-2), whose conformational change upon agon-
ist binding stabilizes the receptor in an active
conformation, facilitating its interaction with coactiva-
tors through the LXXLL motifs [6, 7].
Glucocorticoid resistance, also named Chrousos
syndrome, is a rare, sporadic or familial condition
characterized by biochemically proven hypercortisolism
without the clinical stigmata of Cushing syndrome, and
by partial or generalized insensitivity to glucocorticoids.
Due to this insensitivity, and thereby inadequate negative
feedback, serum ACTH, and therefore cortisol produc-
tion were compensatory stimulated. The chronic excess
of ACTH results in an overstimulated steroid biosyn-
thesis, including increased production of adrenal steroids
with androgenic and/or mineralocorticoid activity [8, 9].
The clinical spectrum ranges from a completely asymp-
tomatic form [10] to severe, life threatening conditions
such as severe hypokalaemia, alkalosis or hypoglycaemia.
In addition, hyperandrogenism (acne, hirsutism, infertil-
ity, oligo-amenorrhea in females, oligospermia and infer-
tility in males, precocious puberty in children) [11] and
mineralocorticoid excess (hypertension and hypokalemic
alkalosis) [12] can also be observed. Fatigue is the most
common sign of the disease [10]. The diagnosis is based
on a detailed evaluation of the hypothalamic-pituitary-
adrenal (HPA) axis. Measurement of serum cortisol
levels in samples collected in the morning under fasting
conditions, at midnight and after dexamethasone admin-
istration, together with evaluation of 24 h urinary-free
cortisol excretion, are mandatory investigations for diag-
nosis. Serum cortisol and 24 h urinary free cortisol
excretion remain elevated after administration of low
dose dexamethasone [13]. Contrary to Cushing’s syn-
drome, in patients with Chrousos syndrome, the HPA
axis preserves its circadian rhythm [13].
To date more than 15 different mutations of the GR
that cause glucocorticoid resistance have been identified.
It has been shown that the mutant receptors may exert a
dominant negative effect on the wild-type receptor, or
may decrease the receptor’s affinity to the ligand. In
addition, a mislocalization of the mutant receptor, de-
layed or failed translocation to the nucleus or decreased
transcriptional activity due to decreased binding through
GRE [11] can lead to glucocorticoid resistance.
Here we present the history of a woman evaluated for
infertility who carries an already published GR gene
variant is considered pathogenic. The phenotypes ob-
served in our cases together with those that have been
published indicate that the same GR gene mutation may
present with variable phenotypes, suggesting that other,
yet not determined factors, may play a role in develop-
ment of GR-associated diseases.
Case presentation
Patient
A 31-year-old woman presented at our Department due
to infertility. Her medical history was unremarkable ex-
cept unsuccessful attempts for pregnancy for the past
2.5 years. She had regular menstrual cycles since the age
of 13 years. On clinical examination, she was normoten-
sive and normokalemic without clinical signs of Cush-
ing’s syndrome or hyperandrogenism. Her height, BMI
and glucose homeostasis and bone mineral density
proved to be normal (height: 170 cm, BMI: 19.8 kg/m2,
fasting serum glucose: 5.0 mmol/l and HbA1c: 5.2%),
and galactorrhoea was absent. Family history was also
unremarkable. Initial laboratory findings indicated an in-
creased serum prolactin level (93 ng/ml; reference range:
1.4–24 ng/ml), but this was due to macroprolactinemia
(prolactin recovery after polyethylene glycol: PEG
precipitation was 76%). Magnetic resonance imaging did
not reveal any pituitary abnormality. A paternal cause of
infertility was unlikely because her husband already had
two children from his previous marriage. Detailed
hormone laboratory investigations of the index patient
suggested a partial resistance against glucocorticoids
(Table 1). After genetic counseling and written informed
consent, Sanger sequencing of the coding region of the
GR gene (NR3C1, NM_000176) was performed. After
identification of a pathogenic GR mutation, a family
screening was indicated for the first degree relatives. Her
35-year-old, clinically healthy sister, who has no fertility
problems (mother of a 10-year-old girl) was also genetic-
ally tested.
All patients and family members underwent genetic
counseling and informed consent for genetic testing was
obtained from all individuals. Evaluation and treatment
of human data have been performed in accordance with
the Declaration of Helsinki and the study was approved
by the Local Ethical Committee of Semmelweis
University.
Laboratory measurements
Laboratory measurements were performed at the
Central Laboratory of Semmelweis University. Fasting
blood samples were obtained between 08:00 and 09:00 h.
Plasma, salivary and urinary cortisol and plasma ACTH,
serum estradiol, progesterone, sex hormone binding
globulin (SHBG), testosterone, luteinizing hormone
(LH), follicle stimulating hormone (FSH), thyroid stimu-
lating hormone (TSH), free thyroxin (fT4), prolactin and
growth hormone (GH) concentrations were measured
with an electrochemiluminescence immunoassay (Cobas
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E411, ROCHE, Indianapolis; Architect System, Lisnamuck,
Longford, Ireland; IDS-iSYS, Immunodiagnostic Systems
Ltd., Boldon, England), while serum dehydroepiandros-
terone sulphate (DHEAS) and androstendione concen-
trations were determined with radioimmunoassay
(Beckman Coulter Brea, California, USA).
Mutation screening of the GR
DNA was isolated from peripheral blood by a standard
procedure using commercially available DNA isolation
reagents (DNA Isolation kit from blood, Qiagen, San
Diego, USA). The whole coding region of the GR was
evaluated by Sanger sequencing as previously described
by Koper et al. [14].
Hormone laboratory findings
Table 1 summarises the main hormone laboratory find-
ings of the index patient. During repeated measure-
ments, serum cortisol levels in the morning were always
elevated (between 26 and 35.4 μg/dl; reference range: 8–
25 μg/dl) while plasma ACTH concentration was slightly
above the upper limit or within the normal range
(between 28.5 and 65 pg/ml; reference range: 7.2–63.3).
Morning salivary cortisol levels (determined two
times) were also elevated (1.36 and 1,13 μg/dl; reference
range: < 0.690) but salivary cortisol collected at midnight
was within the reference range (0.21 and 0.23 μg/dl;
reference range < 0.430 μg/dl). A low dose (1 mg) over-
night dexamethasone suppression test was performed
twice, and showed an inadequate suppression of morn-
ing serum cortisol (10 and 15 μg/dl; reference range: l
< 1.8 μg/dl). Repeated 24 h urinary free cortisol (UFC)
concentrations were between 280 and 513 nmol/day
(reference range: 100–379). Serum DHEAS was slightly
elevated or normal (342 and 163 μg/dl, reference range:
130–330), and serum androstendione was increased
(344 ng/dl; reference range 80-280 ng/dl). GH, SHBG,
TSH, fT4, LH, FSH, testosterone, progesterone and
estradiol levels were all normal (not shown in Table 1).
Sanger sequencing of the coding region of the GR
As shown in Fig. 1, a heterozygous missense mutation
(c.2141G➔A) resulting in a Arg714Gln change was iden-
tified in exon 8 of the GR gene. The same mutation was
found in the clinically healthy 35-year-old sister of the
patient, who had normal steroid hormone levels. Other
family members denied the clinical, genetic or hormonal
screening. In addition, this variant was not detected in
more than 60 patients and controls tested either for
glucocorticoid resistance or Cushing’s syndrome in our
Laboratory. Moreover it was not present in commonly
used genetic databases including Exome Variant Server
(evs.gs.washington.edu/EVS), Exac (exac.broadinstitute.org)
and SNPeffect (http://snpeffect.switchlab.org).
Three-dimensional protein modeling of the Arg714Gln
variant of the GR
Molecular modeling and analyses were performed using
the UCSF Chimera package [15] (Fig. 1b, c). The coordi-
nates of the GR ligand binding domain have been ob-
tained from PDB structure 4UDC. Arginine at the
position 714 is the member of helix 10 of the ligand
binding domain (LBD) of the GR. It locates opposite side
of the ligand binding pocket and relatively far from any
known functional region. However, arginine has a large,
positively charged side chain, which protrudes into a
space created by helices 7–10 (Fig. 1), but glutamine has
a smaller, uncharged side chain, which may release helix
10 from its original position, which may lead to further
conformational changes in the ligand-binding pocket.
Table 1 Laboratory results of the index patient
Parameter Index patient
First visit (range observed during follow-up)
Sister Reference range
Cortisol (μg/dl) 32.4 (26–35.4) 22 8–25
midnight cortisol (μg/dl) 4.8 NA 0–5
morning salivary cortisol (μg/dl) 1.13 (1.13–1.36) NA < 0.69
midnight salivary cortisol (μg/dl) 0.23 (0.21–0.23) NA < 0.43
cortisol after LDDST (μg/dl) 10.1 (10.1–15.1) NA < 1.8
24 h UFC (nmol/day) 513 (208–513) NA 100–379
DHEAS (μg/dl) 163 (163–342) 204 130–330
ACTH (pg/ml) 65 (27–65) 19.9 7.2–63.3
Androstendione (ng/dl) 344 NA 80–280
Prolactin (ng/ml) 93.5 (25.6–93.5) 40.4 1.39–24.2
Prolactin after PEG recipitation 21 (6.1–21) NA 1.39–24.2
LDDST low dose dexamethasone suppression test, UFC urinary free cortisol, DHEAS dehydroepiandrosterone sulfate, ACTH adrenocorticotrop hormone, PEG
polyethylene glycol. All cortisol, DHEAS. androstendione measurements were performed from serum, while for ACTH and prolactin plasma was used Abnormal
results are highlighted in bold
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Nader et al. performed a complex functional testing of
this mutation and using the quantification of the
thickness of both the wild type and mutant Cα
showed that the mutant LBD had an increased dis-
tance in root mean square deviation over the duration
of the simulation compared to the wild type receptor,
suggesting that the mutant structure binds the pep-
tide with less affinity [16].
Discussion and conclusions
In the present study, we identified a missense (R714Q)
variant of the GRgene in a heterozygous form in a young
woman evaluated for infertility. It is particularly interest-
ing that the initial hormonal finding in our patient
revealed hyperprolactinemia, which is a well-known
cause of infertility. However, hyperprolactinaemia was
excluded as a cause of infertility based on the results of
PEG-precipitation, the lack of clinical signs and mag-
netic resonance imaging.
During detailed endocrinological investigation for the
cause of infertility, we demonstrated that our patient has
a mild resistance against glucocorticoids. Sanger sequen-
cing of the coding region of the gene encoding GR was
performed and an already described variant was identi-
fied. The pathogenetic role of the R714Q variant of the
GR gene has already been suggested by Nader et al. who
found this variant in a 2-year-old girl presenting with
hypoglycaemia, hypokalaemia, hypertension, premature
pubarche, mild clitoromegaly, advanced bone age,
elevated cortisol, ACTH, DHEA, androstenedione and
urinary 17-ketosteroid levels [16]. In addition, the
functional consequences of the mutant receptor was also
confirmed, as the mutant receptor displayed a decreased
transcriptional activity with a 2-fold reduction in affinity
to ligand, and a dominant negative effect on the wild-
type receptor [16]. Molecular modeling demonstrated
that substitution of arginine by glutamine in the 714
position of the glucocorticoid receptor may cause con-
formational changes of the ligand-binding pocket, and
the AF-2 domain, leading to an approximately 2-fold
reduction in affinity to ligand [7].
The phenotype difference observed between the pub-
lished case and ours highlights and again confirms that
the clinical manifestation of glucocorticoid resistance is
very heterogeneous (Table 2), and the same mutation
may lead to both severe and mild, even clinically insig-
nificant manifestations.
Treatment of glucocorticoid resistance includes ad-
ministration of a high dose of glucorcorticoids in order
to suppress the excessive ACTH-stimulated secretion of
mineralocorticoids and androgens [13]. However, our
patient had no clinical symptoms of mineralocorticoid
or androgen excess, and it is not known whether a high
dose of glucocorticoids could offer an option for the
treatment of infertility with an acceptable maternal and
fetal risk, and whether glucocorticoids should be contin-
ued during pregnancy. Because the Arg714Glu variant of
the GR gene may cause both mild and severe pheno-
types, a high dose of glucocorticoids may be of value to
prevent fetal androgen and mineralocorticoid excess in
an affected fetus predisposed to a severe phenotype.
Detailed genetic counseling is indicated and prenatal
Fig. 1 Sanger sequencing and three dimensional model of the Arg and Gln at postion 714 of the GR gene. Chromatogram showing the
heterozygous c.2141G➔A mutation of exon 8 of the GR gene in the index patient and her clinically unaffected sister (panel a); Arginine at
position 714 sits on the surface of the domain. The amino acid change from arginine to glutamine may disturb the structure and charge
distribution. The GR ligand binding domain coordinates are from PDB structure 4UDC. The domain backbone represented as ribbon. The
aminoacid 714 and the surrounding residues are represented with sphere and colored CPK. Arginine side change carbon atoms are colored
with light sea green (panel b), while glutamine side change carbon atoms are colored with forest green (panel c)
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genetic testing possible in order to determine the fetus
genotype.
In summary, we present a 31-year-old woman who
was evaluated for infertility and was diagnosed with a
mild phenotype of glucocorticoid resistance caused by
the previously identified, pathogenic Arg714Gln muta-
tion of the GR gene. Its pathogenicity has been sug-
gested by Nader et al. who identified this variant in a
child with a severe disease phenotype [16]. However, we
found this variant in the clinically healthy sister of our
index case, suggesting that the Arg714Gln mutation,
may lead to mild diseases or it can be clinically insignifi-
cant too. Other mechanisms or modifier genes may
explain the phenotype heterogeneity of GR-associated
phenotypes.
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Table 2 Clinical signs of glucocorticoid resistance in previously reported cases
Author [reference] Age (years) Sex GR mutation Clinical signs
Chrousos et al. 1982 [8] 58 Male c.2054A > T, D641V hypertension, hypokalemia
Brönnegard et al. 1986 [17] 46 Female NA fatigue
Karl et al. 1993 [18] 26 Female 4 bp deletion in exon 6 hirsutism, Male-pattern baldness, menstrual irregularities
Malchoff et al. 1993 [19] 6–7 Male c.2317G > A, V729I precocious puberty, hyperandrogenism
Karl et al. 1996 [20] and 33 Male c.1808 T > A, I559N infertility
Kino et al. 2001 [21] 38 Male c.1808 T > A, I559N ACTH producing pituitary adenoma in the same patient
Ruiz et al. 2001 [10] 41 Female c.1430G > A, R477H hirsutism, fatigue, obesity
Ruiz et al. 2001 [10] 31 Female c.2035G > A, G679S hirsutism
Mendonca et al. 2002 [22] 1 day Female homozygous c.1844 T > C, V571A Female pseudohermaphroditism, ambiguous genitalia,
hypertension, hypokalaemia
Vottero et al. 2002 [23] 18 Female c.2373 T > G, I747M cystic acne, hyperandrogenism, hirsutism, oligomenorrhoea
Charmandari et al. 2005 [24] 29 Female c.2318 T > C, L773P fatigue, anxiety, acne, hirsutism
Charmandari et al. 2007 [25] 7 Male c.2209 T > C, F737 L hypertension, hypokalaemia
Charmandari et al. 2008 [11] 43 Female c.1201G > C, D401H tissue-specific glucocorticoid hypersensitivity, obesity,
hypertension, type 2 diabetes, metabolic syndrome
Raef et al. 2008 [26] 19 Male c.2035G > A, G679S hypertension, hypokalaemia, precocious puberty
Nader et al. 2010 [15] 2 Female c.2141G > A, R714Q hypoglycaemia, hypokalaemia, hypertension,
premature pubarche, mild clitoromegaly
McMahon et al. 2010 [27] 1 day Male c.2318_2319delTG, Leu773fs Hypoglycaemia, fatigue, hypertension
Trebble et al. 2010 [28] 20 Female c.1835delC, Arg612fs fatigue, facial hirsutism
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